The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Open accessAbstract
BACKGROUND: Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly progress to glioblastoma. The uncertainty is compounded by interobserver variability in histologic diagnosis. Mutations in IDH, TP53, and ATRX and codeletion of chromosome arms 1p and 19q (1p/19q codeletion) have been implicated as clinically relevant markers of lower-grade gliomas. METHODS: We performed genomewide analyses of 293 lower-grade gliomas from adults, incorporating exome sequence, DNA copy number, DNA methylation, messenger RNA expression, microRNA expression, and targeted protein expression. These data were integrated and tested for correlation with clinical outcomes. RESULTS: Unsupervised clustering of mutations and data from RNA, DNA-copy-number, and DNA-methylation platforms uncovered concordant classification of three robust, nonoverlapping, prognostically significant subtypes of lower-grade glioma that were captured more accurately by IDH, 1p/19q, and TP53 status than by histologic class. Patients who had lower-grade gliomas with an IDH mutation and 1p/19q codeletion had the most favorable clinical outcomes. Their gliomas harbored mutations in CIC, FUBP1, NOTCH1, and the TERT promoter. Nearly all lower-grade gliomas with IDH mutations and no 1p/19q codeletion had mutations in TP53 (94%) and ATRX inactivation (86%). The large majority of lower-grade gliomas without an IDH mutation had genomic aberrations and clinical behavior strikingly similar to those found in primary glioblastoma. CONCLUSIONS: The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic class. Lower-grade gliomas with an IDH mutation either had 1p/19q codeletion or carried a TP53 mutation. Most lower-grade gliomas without an IDH mutation were molecularly and clinically similar to glioblastoma. (Funded by the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gain-of-function IDH mutations are initiating events that define major clinical and prognostic classes of gliomas1,2.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our patient’s tumor harbored mutations in TERT, FUBP1, and CIC, which are common alterations in oligodendroglioma, but not clinically relevant [46,47].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [47]
Experimental — accuracy not yet measuredIn the citing paper
“IDH WT astrocytomas are, for the most part, highly aggressive, having a median survival of 18 mo”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“Second, predicted risks are consistent with the published expected overall survivals associated with molecular subtypes (37).”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“and these have the lowest overall predicted risks consistent with overall survivals of 10+ y (37, 39).”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“IDH mutant astrocytomas are another subtype with considerably better overall survival ranging from 3 to 8 y”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“In recent years, two landmark genomic studies carried out in human glioma and acute myeloid leukaemia (AML) found mutations in IDH1/2 and it is now appreciated that these enzymes (which drive elevated production of D-2-HG) are the most frequently mutated metabolic genes in human cancer112-114.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,656
Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,063
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,706
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Glioma Groups Based on 1p/19q, IDH , and TERT Promoter Mutations in Tumors
Eckel‐Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,981
Flagged first, then by citations
1 of the 54 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Parker BC, 2013, J Clin Invest, 123, 855
Cited by
Sorted by citations
Items 901–1,000 of 1,002
A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis
Koriyama, S., Nitta, M., Kobayashi, T., Muragaki, Y., Suzuki, A., Maruyama, T., Komori, T., Masui, K., Saito, T., Yasuda, T., et al. (2018) · Brain Tumor Pathology · doi:10.1007/s10014-018-0324-1 · Cited by 31
Paradoxes of evidence-based medicine in lower-grade glioma
Duffau, H. (2018) · Neurology · doi:10.1212/wnl.0000000000006288 · Cited by 32
Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
Park, J., & Turcan, Ş. (2019) · Cancers · doi:10.3390/cancers11101616 · Cited by 33
Nuclear receptor 4A2 (NR4A2) is a druggable target for glioblastomas
Karki, K., Li, X., Jin, U.-H., Mohankumar, K., Zarei, M., Michelhaugh, S. K., Mittal, S., Tjalkens, R. B., & Safe, S. H. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03349-y · Cited by 31
Moonlighting Metabolic Enzymes in Cancer: New Perspectives on the Redox Code
Jiang, J., Peng, L., Wang, K., & Huang, C. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8123 · Cited by 31
Pan, Y., Zhu, Y., Zhang, Q., Zhang, C., Shao, A., & Zhang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01057 · Cited by 31
MYD88 Is a Potential Prognostic Gene and Immune Signature of Tumor Microenvironment for Gliomas
Guo, Q., Xiao, X., & Zhang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.654388 · Cited by 31
Duffau, H. (2021) · Cancers · doi:10.3390/cancers13194759 · Cited by 33
Yan, J., Zhang, S., Sun, Q., Wang, W., Duan, W., Wang, L., Ding, T., Pei, D., Sun, C., Wang, W., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00692-5 · Cited by 31
Vega, S. F., Wenger, A., Kling, T., Bontell, T. O., Jakola, A. S., & Carén, H. (2022) · Modern Pathology · doi:10.1038/s41379-022-01113-8 · Cited by 31
Joyner, D., Garrett, J., Batchala, P. P., Rama, B., Ravicz, J. R., Patrie, J. T., Lopes, M.-B., Fadul, C. E., Schiff, D., Jain, R., et al. (2022) · Neuroradiology · doi:10.1007/s00234-022-03038-0 · Cited by 31
Brain network mapping and glioma pathophysiology
Mandal, A. S., Brem, S. S., & Suckling, J. (2023) · Brain Communications · doi:10.1093/braincomms/fcad040 · Cited by 33
Low-grade and anaplastic oligodendroglioma
van den Bent, M. J., Bromberg, J. E. C., & Buckner, J. C. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00022-0 · Cited by 32
Regulation and Dysregulation of Chromosome Structure in Cancer
Hnisz, D., Schuijers, J., Li, C. H., & Young, R. A. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050134 · Cited by 31
Malgulwar, P. B., Danussi, C., Dharmaiah, S., Johnson, W., Singh, A. K., Rai, K., Rao, A. U. K., & Huse, J. T. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad155 · Cited by 31
Xie, X., Shen, C., Zhang, X., Wu, G., Yang, B., Qi, Z., Tang, Q., Wang, Y., Ding, H., Shi, Z., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104899 · Cited by 30
Cabezas-Camarero, S., Pérez‐Alfayate, R., García‐Barberán, V., Gandía-González, M. L., Feijoo, P. G., López-Cade, I., Lorca, V., Casado‐Fariñas, I., Cerón, M. Á., Paz-Cabezas, M., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.02.005 · Cited by 30
Molecular classification of glioma
Killock, D. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.111 · Cited by 30
Disparities in Brain Cancer in the United States: A Literature Review of Gliomas
Persaud-Sharma, D., Burns, J., Trangle, J., & Moulik, S. (2017) · Medical Sciences · doi:10.3390/medsci5030016 · Cited by 30
Isocitrate dehydrogenase 1 mutations in melanoma frequently co‐occur with NRAS mutations
Linos, K. D., & Tafe, L. J. (2018) · Histopathology · doi:10.1111/his.13707 · Cited by 30
Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors
Testa, U., Castelli, G., & Pelosi, E. (2018) · Medical Sciences · doi:10.3390/medsci6040085 · Cited by 33
Chemotherapy Treatment and Trials in Low-Grade Gliomas
Donovan, L. E., & Lassman, A. B. (2018) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2018.08.007 · Cited by 30
Saccà, C. D., Gorini, F., Ambrosio, S., Amente, S., Faicchia, D., Matarese, G., Lania, L., & Majello, B. (2019) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2019.03.004 · Cited by 30
Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses
Liu, Y., Wu, F., Li, J., Li, Y., Liu, X., Wang, Z., & Chai, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01433 · Cited by 30
Chalise, P., Ni, Y., & Fridley, B. L. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.103625 · Cited by 30
Bauer, E. K., Stoffels, G., Blau, T., Reifenberger, G., Felsberg, J., Werner, J., Lohmann, P., Rosen, J., Ceccon, G. S., Tscherpel, C., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04695-0 · Cited by 30
Prognostic and predictive value of an immune infiltration signature in diffuse lower-grade gliomas
Song, L., Weng, J., Li, C.-B., Huo, X., Li, H., Hao, S., Wu, Z., Wang, L., Li, D., & Zhang, J.-T. (2020) · JCI Insight · doi:10.1172/jci.insight.133811 · Cited by 30
Prognostic significance of age related genes in patients with lower grade glioma
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2020) · Journal of Cancer · doi:10.7150/jca.41123 · Cited by 30
Minimalist approaches to cancer tissue-of-origin classification by DNA methylation
Xia, D., Leon, A. J., Cabanero, M., Pugh, T. J., Tsao, M., Rath, P., Siu, L. L., Yu, C., Bedard, P. L., Shepherd, F. A., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0547-7 · Cited by 30
A Practical Overview on the Molecular Biology of Meningioma
López, P. D. D., Cubo-Delgado, E., Gonzalez-Bernal, J. J., & Martín-Alonso, J. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01084-w · Cited by 30
The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes
Hu, D. G., Mackenzie, P. I., Nair, P. C., McKinnon, R. A., & Meech, R. (2020) · Cancers · doi:10.3390/cancers12113369 · Cited by 30
Identification of the Prognostic Signatures of Glioma With Different PTEN Status
Zhang, P., Meng, X., Liu, L., Li, S., Li, Y., Ali, S., Li, S., Xiong, J., Liu, X., Li, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633357 · Cited by 32
Wang, J., Ren, J., Liu, J., Zhang, L., Yuan, Q., & Dong, B. (2022) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2021.6888 · Cited by 30
Park, Y. W., Park, K. S., Park, J. E., Ahn, S. S., Park, I., Kim, H. S., Chang, J. H., Lee, S., & Kim, S. H. (2023) · Korean Journal of Radiology · doi:10.3348/kjr.2022.0732 · Cited by 30
MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Kinslow, C. J., Rae, A. I., Taparra, K., Kumar, P., Siegelin, M. D., Grinband, J., Gill, B. J. A., McKhann, G. M., Sisti, M. B., Bruce, J. N., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1295 · Cited by 31
Zhang, F., Liu, Y., Zhang, Z., Li, J., Wan, Y., Zhang, L., Wang, Y., Li, X., Xu, Y., Fu, X., et al. (2016) · Scientific Reports · doi:10.1038/srep20882 · Cited by 30
Nakae, S., Murayama, K., Sasaki, H., Kumon, M., Nishiyama, Y., Ohba, S., Adachi, K., Nagahisa, S., Hayashi, T., Inamasu, J., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2313-8 · Cited by 30
Thomas, A. A., Abrey, L. E., Terziev, R., Raizer, J. J., Martinez, N., Forsyth, P. A., Paleologos, N. A., Matasar, M. J., Sauter, C. S., Moskowitz, C. H., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox086 · Cited by 30
Capper, D., von Deimling, A., Brandes, A. A., Carpentier, A., Kesari, S., Sepúlveda-Sánchez, J. M., Wheeler, H., Chinot, O. L., Cher, L., Steinbach, J. P., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050995 · Cited by 30
Mutational interactions define novel cancer subgroups
Kuipers, J., Thurnherr, T., Moffa, G., Suter, P., Behr, J., Goosen, R., Christofori, G., & Beerenwinkel, N. (2018) · Nature Communications · doi:10.1038/s41467-018-06867-x · Cited by 31
Mirchia, K., Snuderl, M., Galbraith, K., Hatanpaa, K. J., Walker, J. M., & Richardson, T. E. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0778-3 · Cited by 30
CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition
Nasser, A. M., Melamed, L., Wetzel, E. A., Chang, J. C.-C., Nagashima, H., Kitagawa, Y., Muzyka, L., Wakimoto, H., Cahill, D. P., & Miller, J. J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0562 · Cited by 32
Grading and staging for pituitary neuroendocrine tumors
Villa, C., Birtolo, M. F., Perez‐Rivas, L. G., Righi, A., Assié, G., Baussart, B., & Asioli, S. (2024) · Brain Pathology · doi:10.1111/bpa.13299 · Cited by 29
Further understanding of the pathology of glioma: implications for the clinic
Camelo-Piragua, S. I., & Kesari, S. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1194755 · Cited by 29
Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas
Carter, J. H., McNulty, S. N., Cimino, P. J., Cottrell, C. E., Heusel, J. W., Vigh‐Conrad, K. A., & Duncavage, E. J. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.010 · Cited by 29
Li, N., Zhang, Y., Šidlauskas, K., Ellis, M. J., Evans, I. M., Frankel, P., Lau, J., El-Hassan, T., Guglielmi, L., Broni, J., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0277-1 · Cited by 30
Matoso, A., Idrees, M. T., Rodríguez, F. J., Ibrahim, J., Perrino, C. M., Ulbright, T. M., & Epstein, J. I. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001206 · Cited by 29
Lombardi, A., & Mondelli, M. U. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15449 · Cited by 29
Huang, S., Chan, Y., Huang, S., & Lin, Y. (2019) · Cancers · doi:10.3390/cancers12010013 · Cited by 29
van Lent, D. I., van Baarsen, K. M., Snijders, T. J., & Robe, P. A. J. T. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa044 · Cited by 29
Immunological classification of gliomas based on immunogenomic profiling
Feng, Q., Li, L., Li, M., & Wang, X. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02030-w · Cited by 29
Xu, S., Tang, L., Dai, G., Luo, C., & Liu, Z. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.01.033 · Cited by 29
State of Radiomics in Glioblastoma
Taha, B. R., Boley, D. L., Sun, J., & Chen, C. C. (2021) · Neurosurgery · doi:10.1093/neuros/nyab124 · Cited by 32
Zhang, J., Wang, N., Wu, J., Gao, X., Zhao, H., Liu, Z., Yan, X., Dong, J., Wang, F., Ba, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844778 · Cited by 29
DNA methylation-based epigenetic signatures predict somatic genomic alterations in gliomas
Yang, J., Wang, Q., Zhang, Z.-Y., Long, L., Ezhilarasan, R., Karp, J. M., Tsirigos, A., Snuderl, M., Wiestler, B., Wick, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31827-x · Cited by 29
Munquad, S., & Das, A. B. (2023) · BioData Mining · doi:10.1186/s13040-023-00349-7 · Cited by 30
Low-Grade Gliomas: Histological Subtypes, Molecular Mechanisms, and Treatment Strategies
Toader, C., Eva, L., Costea, D., Corlatescu, A.-D., Covache-Busuioc, R.-A., Bratu, B.-G., Glavan, L.-A., Costin, H. P., Popa, A. A., & Ciurea, A. V. (2023) · Brain Sciences · doi:10.3390/brainsci13121700 · Cited by 31
Grabner, G., Kiesel, B., Wöehrer, A., Millesi, M., Wurzer, A., Goed, S., Mallouhi, A., Knosp, E., Marosi, C., Trattnig, S., et al. (2016) · European Radiology · doi:10.1007/s00330-016-4451-y · Cited by 29
Ricoult, S. J. H., Dibble, C. C., Asara, J. M., & Manning, B. D. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00163-16 · Cited by 29
Progress in neuro-imaging of brain tumors
Castellano, A., & Falini, A. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000328 · Cited by 29
‘Low grade glioma’: an update for radiologists
Larsen, J., Wharton, S. B., McKevitt, F. M., Romanowski, C. A. J., Bridgewater, C. H., Zaki, H., & Hoggard, N. (2016) · British Journal of Radiology · doi:10.1259/bjr.20160600 · Cited by 29
Barresi, V., Lionti, S., Valori, L., Gallina, G., Caffo, M., & Rossi, S. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx024 · Cited by 29
Single-Cell RNA-Sequencing in Glioma
Johnson, E., Mayes, K. D., Connolly, I. D., & Gephart, M. H. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0673-2 · Cited by 29
CHI3L1, NTRK2, 1p/19q and IDH Status Predicts Prognosis in Glioma
Deluche, É., Bessette, B., Durand, S., Caire, F., Rigau, V., Robert, S., Chaunavel, A., Forestier, L., Labrousse, F., Jauberteau, M., et al. (2019) · Cancers · doi:10.3390/cancers11040544 · Cited by 29
Association between extent of resection on survival in adult brainstem high-grade glioma patients
Doyle, J., Khalafallah, A. M., Yang, W., Sun, Y., Bettegowda, C., & Mukherjee, D. R. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03313-w · Cited by 29
A deep neural network approach to predicting clinical outcomes of neuroblastoma patients
Tranchevent, L.-C., Azuaje, F. J., & Rajapakse, J. C. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0628-y · Cited by 29
CNS Tumors in Adolescents and Young Adults: The Need for a Holistic Specialized Approach
Papageorgiou, G., & Razis, E. D. (2020) · JCO Oncology Practice · doi:10.1200/jop.18.00767 · Cited by 29
Ni, J., Zhang, H., Yang, Q., Fan, X., Xu, J., Sun, J., Zhang, J., Hu, Y., Xiao, Z., Zhao, Y., et al. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.02.009 · Cited by 28
Richardson, T. E., Walker, J. M., Hambardzumyan, D., Brem, S. S., Hatanpaa, K. J., Viapiano, M. S., Pai, B., Umphlett, M., Becher, O. J., Snuderl, M., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02761-7 · Cited by 28
Moving the needle: Optimizing classification for glioma
Verhaak, R. G. W. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4740 · Cited by 28
Moure, C. J., Diplas, B. H., Chen, L. H., Yang, R. R., Pirozzi, C. J., Wang, Z., Spasojević, I., Waitkus, M. S., He, Y., & Yan, H. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0309 · Cited by 28
DNA repair genes in astrocytoma tumorigenesis, progression and therapy resistance
de Sousa, J. F., Serafim, R. B., de Freitas, L. M., Fontana, C. R., & Valente, V. (2019) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2019-0066 · Cited by 28
Sirtuin activation targets IDH-mutant tumors
Miller, J. J., Fink, A. L., Banagis, J. A., Nagashima, H., Subramanian, M. P., Lee, C. K., Melamed, L., Tummala, S. S., Tateishi, K., Wakimoto, H., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa180 · Cited by 28
Yang, X., Lin, Y., Xing, Z., She, D., Su, Y., & Cao, D. (2020) · Acta Radiologica · doi:10.1177/0284185120973624 · Cited by 28
Genomic Profiling Identified Novel Prognostic Biomarkers in Chinese Midline Glioma Patients
Li, H., Shan, C., Wu, S., Cheng, B., Fan, C., Cai, L., Chen, Y., Shi, Y., Liu, K., Shao, Y. W., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.607429 · Cited by 28
Garcia-Fabiani, M. B., Haase, S., Comba, A., Carney, S. V., McClellan, B. L., Banerjee, K., Alghamri, M. S., Faisal, S. M., Kadiyala, P., Núñez, F. J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.631037 · Cited by 30
Promoting Prognostic Model Application: A Review Based on Gliomas
Liang, X., Wang, Z., Dai, Z., Zhang, H., Cheng, Q., & Liu, Z. (2021) · Journal of Oncology · doi:10.1155/2021/7840007 · Cited by 28
CpG Island Methylator Phenotype—A Hope for the Future or a Road to Nowhere?
Karpiński, P., & Sasiadek, M. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020830 · Cited by 30
Evolution of Artificial Intelligence-Powered Technologies in Biomedical Research and Healthcare
Díaz-Flores, E., Meyer, T., & Giorkallos, A. (2022) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2021_189 · Cited by 29
Long non-coding RNA in glioma: novel genetic players in temozolomide resistance
Roh, J., Im, M., Kang, J., Youn, B., & Kim, W. (2023) · Animal Cells and Systems · doi:10.1080/19768354.2023.2175497 · Cited by 28
Non-canonical MLL1 activity regulates centromeric phase separation and genome stability
Liang, S., Yang, Z. F., An, S., Yang, W., Kim, S., Oh, H., Xu, J., Yin, J., Wang, H., Lenz, H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01270-1 · Cited by 30
Chen, L., Zhang, J., Chi, C., Che, W., Dong, G., Wang, J., Du, Y., Wang, R., Zhu, Z., Tian, J., et al. (2024) · Theranostics · doi:10.7150/thno.91554 · Cited by 28
Current management of low-grade gliomas
Hottinger, A. F., Hegi, M. E., & Baumert, B. G. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000390 · Cited by 28
Molecular and histologic characteristics of pseudoprogression in diffuse gliomas
Lin, A. L., White, M., Miller‐Thomas, M. M., Fulton, R. S., Tsien, C. I., Rich, K. M., Schmidt, R. E., Tran, D. D., & Dahiya, S. M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2247-1 · Cited by 28
Weston, C. L., Klobusicky, J., Weston, J., Connor, J. R., Toms, S. A., & Marko, N. F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166593 · Cited by 28
Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas
Casar‐Borota, O., Botling, J., Granberg, D. O., Stigare, J., Wikström, J., Boldt, H. B., Kristensen, B. W., Pontén, F., & Trouillas, J. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000908 · Cited by 28
Ross, J., Cooper, L., Kong, J., Gutman, D. A., Williams, M., Tucker‐Burden, C., McCrary, M. R., Bouras, A., Kaluzová, M., Dunn, W. D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15849-w · Cited by 28
Iida, N., Okuda, Y., Ogasawara, O., Yamashita, S., Takeshima, H., & Ushijima, T. (2018) · Epigenomics · doi:10.2217/epi-2017-0093 · Cited by 28
Lee, D. M., Riestenberg, R. A., Haskell-Mendoza, A. P., & Bloch, O. G. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03677-4 · Cited by 28
Zhang, B., Xu, C., Liu, J., Yang, J., Gao, Q., & Ye, F. (2021) · Aging · doi:10.18632/aging.202789 · Cited by 30
Extendable and explainable deep learning for pan-cancer radiogenomics research
Liu, Q., & Hu, P. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.102111 · Cited by 27
Liquid biopsy: creating opportunities in brain space
Trivedi, R., & Bhat, K. P. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02446-0 · Cited by 27
Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas
Hariharan, S., Whitfield, B. T., Pirozzi, C. J., Waitkus, M. S., Brown, M. C., Bowie, M. L., Irvin, D., Roso, K., Fuller, R., Hostettler, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44932-w · Cited by 30
Yuan, J., Siakallis, L. C., Li, H., Brandner, S., Zhang, J., Li, C., Mancini, L., & Bisdas, S. (2024) · BMC Medical Imaging · doi:10.1186/s12880-024-01274-9 · Cited by 27
Patterns of Aneuploidy and Signaling Consequences in Cancer
Zhakula-Kostadinova, N., & Taylor, A. M. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0169 · Cited by 31
Protein Markers Predict Survival in Glioma Patients
Stetson, L. C., Dazard, J.-E., & Barnholtz‐Sloan, J. S. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.060657 · Cited by 27
Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic
Li, Y.-X., Shi, Z., Aibaidula, A., Chen, H., Tang, Q., Li, K. K., Chung, N. Y., Chan, D. T. M., Poon, W. S., Mao, Y. Q., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11378 · Cited by 28
Rodríguez, F. J., Vizcaíno, M. A., Blakeley, J. O., & Heaphy, C. M. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1619-0 · Cited by 29
Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls
Shen, J. P., & Ideker, T. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.026 · Cited by 27
Chen, P., Li, X., Ma, W., Han, L., Li, M., Yang, X., & Li, S.-Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s245896 · Cited by 27
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Affiliations
- Emory University (US)
- Corresponding author
- The Cancer Genome Atlas Research Network
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-25
- Volume
- 372
- Issue
- 26
- Pages
- 2481-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4530011
- OpenAlex
- W1812256879
- Cited by
- 3,148
- References
- 54
- Citations by year
- 2026: 139 · 2025: 196 · 2024: 248 · 2023: 282 · 2022: 371 · 2021: 341 · 2020: 366 · 2019: 314 · 2018: 311 · 2017: 284 · 2016: 226 · 2015: 60
- FWCI
- 164.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, U54HG007990)
- National Cancer Institute (U24CA194362, U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, U24CA143858, U24CA126543, U24CA144025, U24CA126563, U01CA168394, U24CA143866, U24CA143883, U24CA143845, U24CA126544, R01CA163722, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA008748, P30CA016672, U24CA143731)
- National Institute of Neurological Disorders and Stroke (R01NS081125)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glioma molecular subtypes, IDH mutation, 1p/19q codeletion, TP53 mutation, TERT promoter mutation, NOTCH1 mutation, CIC mutation, glioblastoma, prognostic factors, DNA methylation, DNA copy number, gene expression, microRNA expression
- MeSH terms
- Adolescent, Adult, Aged, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 19, DNA, Neoplasm, Female, Glioblastoma, Glioma, Humans, Male, Middle Aged, Mutation, Signal Transduction, Cluster Analysis, Proportional Hazards Models, Genes, p53, Sequence Analysis, DNA, Kaplan-Meier Estimate, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
